#IDT22 scale up pitches

June, 15 2022

The com­pany offers a soft­ware solu­tion in a mix­ture of Saas and AIaaS that greatly sim­pli­fies the cre­ation, test­ing and imple­men­ta­tion of AI sys­tems and can be inte­grated into all devel­oped mod­els and inter­nal sys­tems. This soft­ware solu­tion also enables peo­ple with no knowl­edge of soft­ware devel­op­ment to cre­ate AI systems.
The com­pany has devel­oped a com­mu­ni­ca­tion and mon­i­tor­ing sys­tem that pro­vides real-time feed­back to indi­vid­ual play­ers, groups of play­ers or the entire team dur­ing train­ing. This makes train­ing more effec­tive and sig­nif­i­cantly reduces train­ing interruptions.
The com­pany has devel­oped soft­ware for influ­encer mar­ket­ing in the mid­mar­ket that allows com­pa­nies to build a com­pletely in-house man­aged influ­encer mar­ket­ing process. The soft­ware cov­ers the com­plete mar­ket­ing process for han­dling influ­encer marketing.
The com­pany spe­cial­izes in inno­va­tions for smart cities and urban mobil­ity, in par­tic­u­lar the sus­tain­able imple­men­ta­tion of safe and attrac­tive cycling infra­struc­ture. The data gen­er­ated with a pri­vacy-com­pli­ant safety cam­era is ana­lyzed by means of an Urban Data Plat­form for cities and imple­mented in infra­struc­ture planning.
The com­pany devel­ops and mar­kets human life­like minia­tur­ized organ mod­els from human cells that accu­rately rep­re­sent their biol­ogy and func­tion. This rev­o­lu­tion­izes the devel­op­ment of new active sub­stances by increas­ing the trans­fer­abil­ity of data from drug test­ing to humans.
The com­pany has devel­oped an IT secu­rity solu­tion for SMEs that ensures the secure oper­a­tion of IT with easy-to-under­stand analy­ses and con­crete rec­om­men­da­tions for action. Through this solu­tion, SMEs con­tin­u­ously receive holis­tic secu­rity analy­ses and auto­mated solu­tions against cyber attacks.
The com­pany spe­cial­izes in the pro­duc­tion of smart preser­va­tion and pack­ag­ing solu­tions that pro­vide cor­ro­sion pro­tec­tion even under extreme con­di­tions. It also devel­ops and sells antivi­ral and antibac­te­r­ial materials.
The com­pany has devel­oped a process for pro­cess­ing ther­mo­plas­tics into pow­ders for addi­tive man­u­fac­tur­ing. The result­ing broader range of mate­ri­als with high effi­ciency ensures a much wider range of appli­ca­tions for 3D print­ing, includ­ing mass production.
The com­pany solves the sig­nif­i­cant envi­ron­men­tal impact of fish­ing and fish farm­ing by means of Aqua­cul­ture 2.0 — a new dig­i­tal­ized closed-loop tech­nol­ogy geared to sus­tain­abil­ity. Through this tech­nol­ogy, an edi­ble fish that is exem­plary by both eco­nomic and eco­log­i­cal mea­sures is being raised.
The com­pany offers a novel process tech­nol­ogy for semi­con­duc­tor pro­duc­tion. This tech­nol­ogy opti­mizes the dop­ing of wafers for power semi­con­duc­tors and achieves a pro­duc­tion cost reduc­tion of up to 50%.
The com­pany offers a dig­i­tal ther­apy plat­form for men­tal health care that inte­grates the entire treat­ment chain. Fur­ther­more, it is build­ing its own ther­apy cen­ters to achieve the best pos­si­ble and sus­tain­able ther­apy results for peo­ple with men­tal illnesses.
The com­pany devel­ops and mar­kets highly reli­able, mol­e­c­u­lar bio­log­i­cal tests for early detec­tion, ther­apy deci­sion and fol­low-up in can­cer diagnostics.
The com­pany oper­ates a dig­i­tal, inde­pen­dent mar­ket­place for freight for­ward­ing, where com­pa­nies can com­pare the prices of over 500 freight for­warders and book directly. In addi­tion, the com­pany offers SaaS solu­tions for freight for­warders to sim­plify dig­i­tal­i­sa­tion, save costs and win customers.
The com­pany devel­ops and mar­kets poly­mer addi­tives for plas­tics. These impart opti­mized or even new prop­er­ties to plas­tic prod­ucts, broad­en­ing the range of appli­ca­tions and improv­ing per­for­mance while reduc­ing energy and mate­r­ial con­sump­tion in plas­tics processing.
The com­pany devel­ops and mar­kets inno­v­a­tive dig­i­tal microscopy solu­tions for dig­i­tiz­ing pathol­ogy, thus sup­port­ing med­ical pro­fes­sion­als in rapid micro­scopic assess­ments. The micro­scopes are used dur­ing intra­op­er­a­tive con­sul­ta­tions in can­cer surg­eries and allow pathol­o­gists to ver­ify in sec­onds whether the tis­sue sur­gi­cally removed dur­ing surgery is tumor-free at its edges.
The com­pany acts as a “full-ser­vice provider” for the imple­men­ta­tion of med­ical care pro­grams to pre­vent strokes. Using a screen­ing app, the main cause of stroke is detected and doc­u­mented with ECG-com­pa­ra­ble accuracy.
The company’s multi-dimen­sional index tech­nol­ogy enables the analy­sis of large amounts of struc­tured and unstruc­tured data. The soft­ware can eas­ily be cus­tomised or inte­grated into AI applications.
The com­pany offers quan­tum-based encryp­tion tech­nolo­gies suit­able for both fiber net­works and sys­tems for QKD satel­lite net­works. In addi­tion to QKD tech­nol­ogy, the com­pany will develop com­po­nents and sys­tems for quan­tum com­put­ers and bio­med­ical imag­ing systems.
As a sup­plier to med­ical device man­u­fac­tur­ers, the B2B com­pany devel­ops algo­rithms for cuff-based and cuf­f­less car­dio­vas­cu­lar diag­nos­tics. The focus is on blood pres­sure mea­sure­ment and pulse wave analy­sis, which can be used to pre­dict the devel­op­ment of arte­r­ial dis­eases and high blood pressure.
The tech­nol­ogy com­pany offers hard­ware-based high-speed laser focus­ing that increases the sus­tain­abil­ity of laser pro­duc­tion and laser com­mu­ni­ca­tion, sig­nif­i­cantly accel­er­at­ing laser mate­r­ial processing.
The com­pany offers switch­able pri­vacy prod­ucts via a hard­ware-soft­ware com­bi­na­tion that can be used for mobile devices such as lap­tops, tablets and smart­phones in pub­lic spaces as well as in cars.
The com­pany is devel­op­ing an uni­ver­sal plat­form tech­nol­ogy that can be used to trans­port active phar­ma­ceu­ti­cal sub­stances or other car­gos to spe­cific tar­get cells or tis­sues of the human body.
The highly spe­cialised AI soft­ware com­pany devel­ops and dis­trib­utes secure machine learn­ing algo­rithms for the semi- and fully autonomous mobil­ity of drones, heli­copters, air taxis and vehi­cles. This is made pos­si­ble by the unique fusion of var­i­ous sen­sor tech­nolo­gies with advanced AI algo­rithms and a suit­able, secure sys­tem architecture.
The com­pany devel­ops robots that use sen­sors to detect patients with­out con­tact and eval­u­ate their move­ments and, in the future, vital data. This sup­ports the mobi­liza­tion of patients. In the future, robots will also be used for ther­a­peu­tic and med­ical assessments.
The aim of the com­pany is to close the gap in the forms of pay­ment for travel book­ings. With the solu­tion, credit-financed travel book­ings will be pos­si­ble at the point of sale as well as online in the future.
The com­pany has devel­oped a soft­ware plat­form that enables the dig­i­tal imple­men­ta­tion of clin­i­cally proven ther­a­pies. The plat­form helps both with the imple­men­ta­tion of the ther­apy, net­works the increas­ingly digi­tised obser­va­tion data of the patients with doc­tors and enables direct com­mu­ni­ca­tion with the treat­ing doctor.